Thrombosis
Conference Coverage
New ASH guideline: VTE prophylaxis after major surgery
ORLANDO – The chair of VTE guidelines panel presented highlights of the latest guidelines in a special session at the annual meeting of the...
Conference Coverage
Aspirin plus a DOAC may do more harm than good in some
Adding aspirin to DOAC therapy for the secondary prevention of VTE or the prevention of stroke associated with NVAF without a clear indication...
Conference Coverage
Treating LDL to below 70 reduces recurrent stroke
PHILADELPHIA – Results of TST, a rare cholesterol study in patients with a history of ischemic stroke, explore the benefits of treating to a lower...
Conference Coverage
The TWILIGHT of aspirin post-PCI for ACS?
PHILADELPHIA –
Conference Coverage
GALILEO, GALILEO 4D: Mixed results in post-TAVR anticoagulation
Conference Coverage
Thromboembolic events more likely among CIDP patients with CVAD
AUSTIN, TEX. – Although the study matched patients by demographic factors, researchers did not adjust the analysis for risk factors or confounders...
News from the FDA/CDC
FDA approves rivaroxaban for VTE prevention in hospitalized, acutely ill patients
The latest approval is based on results from the phase 3 MAGELLAN and MARINER trials, which included more than 20,000 patients.
From the Journals
Rivaroxaban trends toward higher thrombotic risk than vitamin K antagonists in APS
Patients who took rivaroxaban experienced almost two times as many thrombotic events as patients who took dose-adjusted vitamin K antagonists.
Conference Coverage
Ticagrelor monotherapy tops DAPT for high-risk PCI patients
SAN FRANCISCO – TWILIGHT findings support move to shorter DAPT.
From the Journals
Older IBD patients are most at risk of postdischarge VTE
Readmission for venous thromboembolism in patients with inflammatory bowel diseases most often occurs within 60 days of discharge.
Conference Coverage
POP AGE shakes up DAPT in elderly
PARIS – Clopidogrel hailed as P2Y12 inhibitor of choice in older patients with non-ST-elevation ACS.